Sorafenib targets the Raf/mitogen-activated protein kinase, VEGF, and platelet-derived
growth factor pathways and prolongs survival patients in advanced hepatocellular …

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a particularly vascularized solid
tumor where the Raf/MEK/ERK pathway is activated; suggesting that inhibition of this …

BACKGROUND & AIMS: The combination of erlotinib with sorafenib is currently being
investigated in a phase III RCT. We studied the effect of erlotinib and sorafenib on HCC in a …

4074 Background: The PI3K/Akt/mTOR pathway, a key regulator of cellular proliferation and
angiogenesis, has emerged as a contributor to hepatocarcinogenesis. Everolimus, an …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …

Surgical resection is the first‐line treatment for hepatocellular carcinoma (HCC) patients with
well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is …

ABSTRACT Angiogenesis and RAS/RAF/MEK/ERK pathway have been demonstrated to be
relevant in hepatocellular carcinoma (HCC). Sorafenib, an oral multikinase inhibitor with …

Sorafenib, a multikinase inhibitor with antiangiogenic activity, is an approved therapy for
hepatocellular carcinoma (HCC). It is unclear whether the proinflammatory and …

BACKGROUND & AIMS: Sorafenib is the standard of care for the treatment of advanced
hepatocellular carcinoma (HCC). However, primary and acquired resistance is observed in …